Hyperfine has announced the first commercial sales of its next-generation Swoop system powered by proprietary Optive artificial intelligence (AI) software to two leading hospitals in the northeast of the USA. Both of these “pioneering” hospitals plan to utilise the technology in intensive care units and emergency department settings, according to a Hyperfine press release.
The release goes on to posit that initial sales of the next-generation Swoop system demonstrate a “strong market response” following US Food and Drug Administration (FDA) clearance and mark a “critical step” toward the widespread clinical adoption of portable brain imaging with diagnostic-level clarity.
“This marks the start of a new phase for Hyperfine—one where our vision to transform MRI [magnetic resonance imaging] access is driven by a new system that is commercially ready, is clinically valuable, has outstanding image quality and functionality, and is garnering strong customer interest,” commented Maria Sainz, president and chief executive officer (CEO) of Hyperfine. “Attaining the milestone of first commercial sales and deliveries of the new Swoop system just weeks after FDA clearance is the result of seamless execution across the organisation—from industry-leading product development to accelerated clearance, to rapid manufacturing ramp to initial sales. We are excited about the momentum with the new Swoop system, and the growth we anticipate in the second half of 2025 and beyond.”
Hyperfine claims that the new Swoop system features innovations specifically engineered to deliver the highest signal-to-noise ratio—which, when paired with the company’s Optive AI software, achieves exceptional image quality, including improved resolution and uniformity, and faster acquisition times.
This new level of image quality has the potential to “dramatically drive” the adoption of the Swoop system across sites of care and multiple clinical applications, the release adds, also noting that the new Swoop system delivers a user- and patient-centric design to accommodate a broad patient population, which is especially beneficial for paediatric, elderly or anxious patients, and will help make MRI more accessible for all.
